CA-PACSCI-EMC
17.3.2020 15:02:07 CET | Business Wire | Press release
Pacific Scientific Energetic Materials Company (California), LLC. (PacSci EMC) announced today the execution of a Memorandum of Understanding with Space Information Laboratories (SIL) to provide plug-and-play Autonomous Flight Termination Systems (AFTS) for launch vehicles, missiles, hypersonic vehicles, reentry vehicles, strike weapons and unmanned aerial systems. PacSci EMC Safe and Arm high voltage electronics will be integrated with the SIL Vehicle Based Independent Tracking System (VBITS) AFTU with internal GPS L1/L2 Receivers, IMU, together in a Consolidated Avionics® unit with reduced Space, Weight and Power (SWAP) requirements. Attributes include open, modular, stackable and reconfigurable (OMSR) avionics.
“SIL has very unique, leading-edge technology for the AFSS mission that when combined with the PacSci EMC flight qualified ordnance flight termination system provides a low cost, comprehensive solution for this critical need,” said Greg Scaven, President, PacSci EMC. “The AFSS architecture is RCC-319 compliant with the flexibility and safety necessary for platform success, and the system can be customized for unique applications.”
SIL is a leading provider of high-end Li-Ion Polymer Intelli-Pack® Avionics/Telemetry and FTS Batteries, VBITS GPS Tracking and Autonomous Flight Termination Systems (AFTS), Space Based Range, and Consolidated Avionics® flight units for DoD programs of national significance. Originally developed in 2006, VBITS has successfully flown many times without loss of GPS receiver lock and this heritage is being leveraged. SIL’s patented Vehicles Based Independent Range System (VBIRS) will track, destroy and send high data rate BLOS telemetry without the need for ground range instrumentation Radar, Flight Termination and/or Telemetry Systems, and thus greatly reduces launch, and weapon system test and evaluation, costs.
Edmund Burke, President of Space Information Laboratories, said: “I am very impressed with PacSci EMC’s broad product offering and technical capabilities. They rapidly filled a need for us that will result in accelerated growth.”
About Pacific Scientific Energetic Materials Co.
PacSci EMC provides state-of-the-art safe and arm high voltage electronics firing circuitry for multiple DoD and commercial launch vehicle, missile, weapons and aircraft. PacSci EMC missile control safety and arming products are suitable for application in all weapon systems. PacSci EMC has seven decades of pyrotechnic and energetic materials experience for mission and flight critical safety systems. (https://psemc.com )
About Space Information Laboratories
Headquartered in Santa Maria, CA near Vandenberg AFB, SIL is a world-class small business supplier of innovative avionics and power system technologies and solutions for mission-critical programs for the MDA, NAVAIR, USAF, DARPA, Aerospace Industry, and other U.S. Government Agencies. SIL’s expertise includes development and production of Li-Ion Polymer Intelli-Pack® batteries, Intelli-Avionics®, VBITS GPS Tracking and Autonomous Flight Termination System, Space Based Range and Chameleon 12U to 27U Flexible Bus product lines. SIL is AS9100D Quality Management System certified to design, manufacture and test flight units. (www.spaceinformationlabs.com )
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005002/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 13:20:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 13:15:00 CEST | Press release
Xsolla Heads to Berlin to Advance and Foster Private Capital Relationships, Advance and Engage Senior Investors Across the Private Capital Ecosystem Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom